Steffen Rossner

Dr. Steffen Rossner


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2006 in Progress in Neurobiology
Verified
Journal Article
Closed access
SRSteffen Rossner
Steffen Rossner
MSMagdalena Sastre
Magdalena Sastre
KBKrystyn Bourne
Krystyn Bourne
SLStefan F. Lichtenthaler
Stefan F. Lichtenthaler

9 December 2004 in Journal of Neurochemistry
Verified
Journal Article
Closed access
PDF file
SRSteffen Rossner
Steffen Rossner
CLChristine Lange-Dohna
Christine Lange-Dohna
UZUlrike Zeitschel
Ulrike Zeitschel
JPJ Regino Perez-Polo
J Regino Perez-Polo

30 June 2005 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
ISIngo Schulz
Ingo Schulz
UZUlrike Zeitschel
Ulrike Zeitschel
TRThomas Rudolph
Thomas Rudolph
DRDavid Ruiz‐Carrillo
David Ruiz‐Carrillo
JRJens‐Ulrich Rahfeld
Jens‐Ulrich Rahfeld
SRSteffen Rossner
Steffen Rossner
For a long time, prolyl endopeptidase (PEP) was believed to inactivate neuropeptides in the extracellular space. However, reports on the intracellular activity of PEP suggest additional, as yet unidentified, physiological functions for this enzyme. Here, we demonstrate using biochemical methods of subcellular fractionation, immunocytochemical double‐labelling procedures and localization of PEP–enhanced green fluorescent protein fusion proteins that PEP is mainly localized to the perinuclear space, and is associated with the microtubulin cytoskeleton in human neuroblastoma and glioma cell lines. Disassembly of the microtubules by nocodazole treatment disrupts both the fibrillar tubulin and PEP labelling. Furthermore, in a two‐hybrid screen, PEP was identified as binding partner of tubulin. These findings indicate novel functions for PEP in axonal transport and/or protein secretion. Indeed, a metabolic labelling approach revealed that both PEP inhibition and PEP antisense mRNA expression result in enhanced peptide/protein secretion from human U‐343 glioma cells. Because disturbances in intracellular transport and protein secretion mechanisms are associated with a number of ageing‐associated neurodegenerative diseases, cell‐permeable PEP inhibitors may be useful for the application in a variety of related clinical conditions.

1 June 2005 in Neurochemical Research
Verified
Journal Article
Closed access
PDF file
SRSteffen Rossner
Steffen Rossner
ISIngo Schulz
Ingo Schulz
UZUlrike Zeitschel
Ulrike Zeitschel
RSReinhard Schliebs
Reinhard Schliebs
VBVolker Bigl
Volker Bigl
HDHans-Ulrich Demuth
Hans-Ulrich Demuth

1 April 2003 in Neurochemical Research
Verified
Journal Article
Closed access
PDF file
MBMike Beck
Mike Beck
VBVolker Bigl
Volker Bigl
SRSteffen Rossner
Steffen Rossner

1 May 2007 in European Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
SRSabrina Reimers
Sabrina Reimers
MHMaike Hartlage‐Rübsamen
Maike Hartlage‐Rübsamen
GBGert Brückner
Gert Brückner
SRSteffen Rossner
Steffen Rossner